Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Gross Margin (2016 - 2025)

China Pharma Holdings' Gross Margin history spans 16 years, with the latest figure at 12.3% for Q4 2025.

  • For Q4 2025, Gross Margin rose 2646.0% year-over-year to 12.3%; the TTM value through Dec 2025 reached 3.18%, up 4066.0%, while the annual FY2025 figure was 3.18%, 4066.0% up from the prior year.
  • Gross Margin reached 12.3% in Q4 2025 per CPHI's latest filing, up from 7.89% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 12.3% in Q4 2025 to a low of 109.78% in Q2 2024.
  • Average Gross Margin over 5 years is 12.48%, with a median of 9.52% recorded in 2022.
  • Peak YoY movement for Gross Margin: plummeted -9642bps in 2024, then skyrocketed 10130bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 10.45% in 2021, then tumbled by -86bps to 1.46% in 2022, then tumbled by -352bps to 3.68% in 2023, then tumbled by -285bps to 14.16% in 2024, then skyrocketed by 187bps to 12.3% in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Gross Margin are 12.3% (Q4 2025), 7.89% (Q3 2025), and 8.48% (Q2 2025).